

ESTRO



ANNUAL
REPORT
L 2022

Editorial	PAGE 3
Mission	6

4 ESTRO Cancer Foudation (ECF)	PAGE 52
---------------------------------------	-------------------

1 Science & dissemination	PAGE 7
MEETINGS	8
1. ESTRO 2022	8
2. Joint & collaboration events	12
3. ESTRO workshops	17
PUBLICATIONS	20
1. The Green Journal	20
2. Open access journals	23
RESEARCH & DISSEMINATION	31
GUIDELINES	34

5 Financial report	PAGE 54
1. Treasurer's report for 2022	55
2. ESTRO audited accounts 2021	56
3. Cumulative result 2008-2022	57

2 ESTRO School	PAGE 35
1. Teaching courses	37
2. E-Learning	40

6 Annex	PAGE 58
1. Governance & constituent bodies	59
2. Staff	62
3. Corporate members	62
4. Joint members	63
5. RTT alliance	63
6. Institutional members	64
7. Radiotherapy and Oncology and open access journals	65
8. Awards	67
9. Newsletter	67

3 Membership & partnerships	PAGE 43
MEMBERSHIP	44
1. Profile of ESTRO members	45
2. Wide range of membership categories	47
3. Membership categories under the spotlight	48
RTT Alliance	51
MoUs	51

Editorial

Three years on from parts of Europe entering their first lockdown, we find ourselves in a very different world and ESTRO, in common with its members, has had to adapt and evolve accordingly. 2022 has been a year of particularly rapid change in many areas but these changes have been underpinned by a renewed sense of community. We have been reminded of the immense value in working together for the good of those we serve but also the enormous joy of face-to-face human collaboration.

Events

I start this report with a reflection on the ESTRO 2022 Congress. The sunlit lowlands of Copenhagen were a glorious backdrop for ESTRO's return to fully-fledged face-to-face conferencing, building on the momentum created by ESTRO 2021. ESTRO 2022 brought together 5,700 stakeholders from across the radiation oncology community. The excitement of colleagues seeing old friends for the first time in years was palpable. Many were also reminded that the opportunity to be away from the day job, deep-diving and discussing the latest research and innovations, is a powerful catalyst for clinical and academic endeavours the rest of the year. For those who couldn't make it in person (and for those that couldn't be in two excellent sessions at once), most of the plenary sessions, symposia and proffered paper sessions were available for leisurely digestion after the event. For the more intimate, and incredibly popular, mini-oral sessions you simply had to be there, and these sessions will be a key component of annual ESTRO congresses going forwards.

Of course, radiation oncology professionals need recharging year-round and this is where ESTRO looks to diversify its offerings going forwards. Workshops, for example, have proved hugely popular and productive. ESTRO organised three highly successful workshops in 2022: the Physics Workshop (Lisbon, 7-8 October 2022) and the GEC-ESTRO Workshop (Nice, 1-2 December 2022) were organised onsite and gathered 156 and 190 participants respectively, whilst the RTT Workshop brought together 65 delegates in a fully online event (15 November 2022 and 16 February 2023). The workshop model as a means of bringing smaller specific interest groups to brainstorm issues of current interest is one that ESTRO seeks to replicate across the society. Focused interactions at the junctures between radiation oncology disciplines have the potential to be particularly fruitful.

Membership

ESTRO membership has increased by around one third over the last decade, 2022 marking an all-time high with nearly 8,300 ESTRO members by the end of the year. Institutional membership continues to represent a large portion of the society's membership, alongside an increasing number of associations entering into joint membership agreements with ESTRO. Membership proportions are relatively stable with around half of ESTRO members being clinicians, around a quarter medical physicists and around 20% RTTs. ESTRO is keen to grow its radiation biology community as well as providing a home for other radiation-research associated specialities not currently formally represented in our structure.

Education

The ESTRO School built on the achievements of 2021, continuing to deliver a rich and diversified educational portfolio both in content and mode of delivery. While many ESTRO courses were reinstated face-to-face, the School leveraged the opportunities of the online environment to enrich its programmes, be it through recorded lectures, blended courses, or fully online curricula. 2022 confirmed the ESTRO School's ability to integrate the benefits of the online environment into its educational output. In

2022, 25 courses were organised with a total of 1,879 students, 6 courses having taken place online. In parallel, FALCON contouring workshops continued a steady growth trend, with 432 registered participants for 13 workshops confirming an increasing appetite for being able to access at least some aspects of radiotherapy training online.

Science & dissemination

The ESTRO family of journals continued to grow in 2022 with *ctRO* obtaining its first Impact Factor in 2021, an impressive 4.739. Site activation for the E²-RADIatE platform saw a steady increase and the OligoCare cohort continued to recruit very well with around 1,680 patients enrolled as of November 2022. ESTRO joined forces with other associations and stakeholders to respond to EU calls for tenders resulting in the EU-REST and MARLIN projects being launched whilst the QuADRANT project concluded in 2022. ESTRO also increased its efforts to streamline guideline initiatives internally, publishing nine internal and joint guidelines and endorsing five guidelines developed by other societies.

Society Affairs

After a brief COVID-19-related hiatus, the ESTRO governance review made a significant leap forward, with Board members and Chairs of all ESTRO governance bodies coming together to resume wider discussions on how to improve accountability, transparency and access within the society. The ESTRO Governance Review White Paper was approved by the Board in September 2022, with the newly formed Professions and Partnerships Council beginning its work the same month. Focus Groups, the new creative think-tanks of our society were approved for launch in 2023 and more detail on these will follow in next year's report.

Four years on from the publication of the ESTRO Vision 2030, the society also started preparations for a 2023 strategy retreat with the aim of taking stock post-pandemic, reviewing the needs of our community and therefore determining strategic objectives for the next 3- 5 years. Top line recommendations will be presented at the 2023 ESTRO General Assembly.

Partnerships

2022 saw renewed Memoranda of Understanding (MoUs) with many national and international partners, including professional associations, site-specific societies and research organisations. The MoUs signed in 2022 were largely multi-area agreements defining ESTRO's role in joint courses and events, joint membership partnerships, as well as the initiation and endorsement of scientific content. While a large number of stakeholders included European associations, ESTRO also confirmed key partnerships in North America and Australasia. In particular, a new edition of the ESTRO meets Asia congress which will be organised with the Federation of Asian Organizations for Radiation Oncology (FARO) in 2024.

In summary, 2022 has seen ESTRO demonstrate an extraordinary capacity to adapt to the changing needs of the radiation oncology community and the patients it serves. The benefits of working together as one body with one vision, purpose and voice have become even clearer and ESTRO's new governance structure will underpin focused, inclusive, fruitful and clearly-communicated collaboration between like-minded and energetic individuals. ESTRO has a unique interdisciplinary culture from which we can all benefit. Thanks to the sense of togetherness and spirit shown by our community, we have been able to turn the post-pandemic corner and set the foundations for a stronger and healthier society guided still by ESTRO's 2030 Vision "Radiation Oncology, Optimal Health For All, Together". Thank you for being part of this vision.

Anna Kirby
ESTRO President

Radiation Oncology.
Optimal Health
Together. **FOR ALL,**

- ESTRO VISION 2030 -

VISION 2030 STRATEGIC AREAS

From research to practice
Strengthening the profession
Strengthening the society
Strengthening partnerships

Mission

The mission of ESTRO, a non-profit, scientific organisation, shall be to foster, in all its aspects, radiotherapy (also known as radiation oncology), clinical oncology and related subjects, including physics as applied to radiotherapy, radiation technology and radiobiology.

To fulfil its mission ESTRO will:

- └ Develop and promote standards of education in radiotherapy and clinical oncology
- └ Promote standards of practice in radiotherapy, clinical oncology and related subjects
- └ Stimulate the exchange of scientific knowledge in all related fields
- └ Strengthen the clinical speciality of radiotherapy and clinical oncology in relation to other specialities and professions involved in cancer management
- └ Encourage co-operation with international, regional and national societies and bodies representing radiotherapy, clinical oncology and related subjects
- └ Facilitate research and development in radiotherapy, clinical oncology and related subjects.

1 SCIENCE & DISSEMINATION

ESTRO has a long track record of organising conferences, disseminating the latest findings and providing a platform for networking hence working towards optimal care for cancer patients.



MEETINGS

1. ESTRO 2022

The Annual Congress of the European Society for Radiotherapy and Oncology

6-10 May 2022 | Copenhagen, Denmark

ESTRO 2022 covered the wide spectrum of radiation oncology through 12 tracks delivering sessions in six different fields, reflecting the highly specialised disciplines of the radiation oncology area:

- Clinical
- Brachytherapy
- Physics
- RTT (Radiation Therapists)
- Radiobiology
- Young.

An interactive hybrid format

Delegates could attend the congress onsite in Copenhagen but they could also join online thanks to a platform that enabled interaction between onsite and online participants. All sessions were live-streamed and recorded to be available on-demand. This allowed all delegates, both onsite and online, to attend a maximum number of sessions.

A top-level scientific programme

Although delegates could join online, all faculty present onsite provided the best audience experience. The latest science in radiation oncology was delivered via symposia, teaching lectures, debates, pitch sessions and panel discussions as well as proffered papers.

Improved presentation formats

New, highly-interactive mini-oral and poster discussion sessions promoted great interaction between presenters and the audience and gave more visibility to submitted work and research.

Young programme

A programme for young delegates was delivered on a dedicated day to provide those in the early stages of their career with the information and tools to make the most of their professional opportunities.

A host of educational activities

In addition to the main scientific programme, several pre-meeting courses and contouring workshops were held. These are discussed in the School section of this report.

PARTICIPATION

5,663 Delegates



67% Participants
33% Company delegates




90% Onsite participations
10% Online participations

Most Represented Specialities




42% Radiation Oncologists	Onsite: 80%	Online: 20%
27% Medical Physicists	Onsite: 90%	Online: 10%
13% RTTs, RT Nurses	Onsite: 91%	Online: 9%
10% Clinical Oncologists	Onsite: 79%	Online: 21%
2% Radiobiologists	Onsite: 95%	Online: 5%
1% Dosimetrists	Onsite: 93%	Online: 7%
1% Computer Scientists	Onsite: 93%	Online: 7%
1% Medical Oncologists	Onsite: 97%	Online: 3%



Top 8 countries



Evolution of participation to the ESTRO congress




Gender



Average
44 years old

EXHIBITION

110 Exhibitors (online & onsite)




 **1,924**
Abstracts

 **1,136**
Posters

 **329**
Chairs

 **232**
Sessions

 **288**
Invited Speakers

 **4,754**
Sqm

2. Joint and collaboration events 2022

2.1 ICHNO-ECHNO 2022

International Congress on Innovative Approaches in Head and Neck Oncology (ICHNO) joint with the European Congress on Head and Neck Oncology (ECHNO)

3-5 March 2022 | Brussels, Belgium

The ICHNO-ECHNO congress provided a unique platform for the dissemination of the most relevant and cutting-edge science and innovation in the field of head and neck oncology.

Organised by ESTRO, the European Head and Neck Society (EHNS) and the European Society for Medical Oncology (ESMO), ICHNO-ECHNO has been shaped into a major international event in the promotion of multidisciplinary head and neck oncology.

Due to the Covid-19 restrictions, the congress was offered in a hybrid format, participants could attend it onsite in Brussels or online.

CONFERENCE



174
Abstracts



17
Sessions



35
Invited Speakers
(29 onsite, 6 online)



25
Chairs



21
Oral Presenters
(13 onsite, 8 online)


EXHIBITION



63
Sqm



4
Exhibitors




3
Associations

530 Delegates



- 225 Onsite
- 305 Online

Top 10 countries



Breakdown per speciality



- |||| 48% RO Speciality
 - 22,8% Radiation Oncologist
 - 20,6% Clinical Oncologist
 - 1,5% Medical Physicist
 - 1,5% Other
 - 0,9% Medical Oncologist
 - 0,4% Radiobiologist
 - 0,2% RTT, RT nurse
- 19,2% Other Medical Specialities
- 17,9% Not specified
- 14% RO Industry - Corporate
- 0,9% Other Non-medical Specialities


2.2 European Lung Cancer Conference (ELCC 2022)

30 March - 2 April 2022 | Online


Organised by ESMO (European Society for Medical Oncology) and IASLC (International Association for the Study of Lung Cancer) with ESTRO, European Society of Thoracic Surgeons (ESTS) and the European Thoracic Oncology Platform (ETOP) as partners.

The ELCC is a collaboration of the most important multidisciplinary societies that represent thoracic oncology specialists, working together to advance science, disseminate education and improve the practice of lung-cancer specialists worldwide.


Medical oncologists, radiation oncologists, thoracic surgeons, respiratory physicians/pneumologists, interventional radiologists and pathologists all benefit from its comprehensive programme.




Breakdown of participants




Breakdown per speciality



Top 10 countries



Gender




2.3 European Multidisciplinary Congress on Urological Cancers (EMUC 2022)

Working together to improve patient care


10-13 November 2022 | Budapest, Hungary - *Jointly organised by EAU, ESMO and ESTRO*

The 14th European Multidisciplinary Congress on Urological Cancers (EMUC22) placed a specific emphasis on the importance of a multi-sectoral approach in the treatment of genitourinary (GU) malignancies.


The EMUC22 scientific programme highlighted the most recent developments in the prevention, diagnosis and best practices in the management of GU cancers.



Top 10 countries



Gender



2.4 Endorsed Events

ESTRO endorsed 30 conferences, congresses and courses in 2022.

14th Breast Gynecology Immunology International Cancer Conference (BGIICC)

20-21 January 2022 | Cairo, Egypt

ATM 2022

17-19 February 2022 | Assisi, Italy

5th Conference on Small Animal Precision Image Guided Radiotherapy

21-23 March 2022 | Munich, Germany

International Conference on Monte-Carlo Techniques for Medical Applications

11-13 April 2022 | Antwerp, Belgium

Niels Bohr Course on Therapeutic and Diagnostic Medical Physics

2-5 May 2022 | Herlev, Denmark

ISRS 2022

19-23 June 2022 | Milan, Italy

10th Bucharest Oncology School: New Horizons

20-23 June 2022 | Bucharest, Romania and online

11th International Gastrointestinal Liver Urological Cancer Conference (IGILUC)

21 -22 July 2022 | Cairo, Egypt

Cervix Cancer BT Teaching Course

1 September 2022 - 1 January 2023 | Online

26th Annual SASRO Meeting

1-3 September 2022 | Baden, Switzerland

Radiomics Toolbox Workflow and Quality Management

7-9 September 2022 | Pavia, Italy

Workshop on Clinical Translation of FLASH Therapy

15 September 2022 | Lausanne, Switzerland

New Modalities in Cancer Imaging and Therapy Workshop

5-8 October 2022 | Ergquy, France

2nd International Radiation Oncology Virtual Seminar

6 October 2022 | Online

Arab African International Cancer Congress 2022 (AAICC)

6-7 October 2022 | Cairo, Egypt and online

Modern Radiotherapy Oncology: Multidisciplinary Approaches in the Age of Treatments Guided by Omics Sciences and Artificial Intelligence

7 October 2022 | Olbia, Italy

5th Congress of SEETRO

7-9 October 2022 | Skopje, North Macedonia

3rd Ion Imaging Workshop

13-14 October 2022 | Munich, Germany

New Avenues in the Non-Operative Management of Patients with Rectal Cancer: Time for Discussion

13-15 October 2022 | Montreal, Canada

AI Meets Head & Neck Oncology

14-15 October 2022 | Lausanne, Switzerland

32nd Residential Course on Modern Radiation Oncology: Multidisciplinarity in the Era of Omics and AI Guided Oncology

17-19 October 2022 | Rome, Italy

18th Meet the Professor Advanced International Breast Cancer Course

3-4 November 2022 | Padova, Italy and online

VIII ALATRO Congress

16-18 November 2022 | Lima, Peru

Particle Therapy Teaching Course

17-25 November 2022 | Online

Think Hadrom: Discovering Hadrontherapy within Multidisciplinarity

21 November, 12 December 2022 & 15 February 2023 | Online

XXXII AIRO National Congress

25-27 November 2022 | Bologna, Italy

FLASH Radiotherapy and Particle Therapy (FRPT 2022)

30 November - 2 December 2022 | Barcelona, Spain & online

1st MESTRO Meeting

1-2 December 2022 | Riyadh, Saudi Arabia

Workshop on Patient QA - Use of Advanced Dosimetry Techniques

1-4 December 2022 | Novi Sad, Serbia

Masterclass: Artificial Intelligence, Medical Physics and Radiation Oncology

12-15 December 2022 | Villejuif, France

3. ESTRO Workshops

3.1 2022 Physics Workshop - Science in development

7-8 October 2022 | Lisbon, Portugal

The physics workshops, organised by the ESTRO Physics Committee, are designed to create forums for discussion of topics of interest, the sharing of ideas, the development of joint projects and interaction with industry partners. The workshops were set up in 2017 to enable small numbers of people to come together to focus on specific 'hot' topics and how to move them forward.

Five tracks ran in parallel:

- └ Re-irradiation: improving dose summation for plan
- └ Joint DREAM (Dose Response, Experiment, Analysis, Modelling): a physics & radiobiology workshop
- └ Justification and optimisation of KV imaging in IGRT
- └ Particle Arc Therapy: from concept to clinical reality
- └ Next generation MR-guided radiotherapy: AI applications for planning and image guidance.

152 Delegates




- 141 Participants
- 11 Company delegates

Top 5 disciplines



- 61% Medical Physicists
- 23% Radiation oncology Industry
- 6% Radiobiologists
- 2% RTTs (Radiation Therapists)
- 1% Dosimetrists
- 7% Other or not specified

Top 5 countries (Participants)



3.2 GEC-ESTRO Workshop 2022 - Improving Brachytherapy Together


1-2 December 2022 | Nice, France

The GEC*-ESTRO annual workshop is now a hallmark platform for networking with the seven GEC-ESTRO working groups (Anal-rectal, Brachy-HERO, BRAPHYQS, Breast, Gynae, Paediatric, Head and Neck and Skin, UroGEC).


The 2022 edition covered multiple exciting new aspects of brachytherapy. Each working group presented and analysed a site-specific aspect of modern, image-guided brachytherapy. In addition to the scientific programme, the format of the workshop offered networking opportunities and educational activities with parallel and repeating sessions including industry.

*GEC : The Groupe Européen de Curiethérapie


185 Delegates



Top 5 disciplines



Top 5 countries (Participants)



3.3 2022 RTT Workshop


15 November 2022 & 16 February 2023 | ONLINE

The RTT workshops aim to facilitate scientific collaborations and professional networking within the ESTRO RTT community and to establish recommendations on the future roles of RTT.

The workshop proposed three sessions:

- └ Evaluation of RTT education - is it fit for the present
- └ RTT-ADAPT: Enabling the Radiation Therapist (RTT) to embrace future roles through the lens of new technology
- └ RTT advance practice and how it can change the future of radiotherapy.

64 Delegates



Top 5 disciplines



- 88% RTTs, RT Nurses
- 3% Dosimetrists
- 9% Other

Top 5 countries (Participants)



PUBLICATIONS

1. The Green Journal

Editor-in-chief: Michael Baumann (Heidelberg, Germany)

Radiotherapy and Oncology, known as the *Green Journal*, is the flagship publication in ESTRO's family of journals. It covers all aspects of radiation oncology, publishing themed issues, editorials and correspondence, as well as original research and review articles.


Article transfer service

to *CtRO*, *PhiRO* and *TipsRO*

For manuscripts not selected for publication in *Radiotherapy and Oncology*, authors may be provided with the option of having their manuscript transferred to an ESTRO Open Access publication.

SUBMITTED PAPERS

Manuscript submissions



1,764 submitted manuscripts


- 366 Accepted
- 1,323 Rejected
- 23 Withdrawn or removed

78% REJECTION RATE

154 (11.6% of the rejected articles) articles were transferred to *ctRO*, *phiRO* or *tipsRO* and


89 (6.7% of the rejected articles) were accepted for publication in the open access journals.

Submitted articles by region




- 29% Europe
- 16.5% North and Central America
- 51.5% Asia
- 2% Oceania
- 1% South America

Evolution of the number of articles submitted



ACCEPTED PAPERS


Top 10 countries of accepted papers



*The region and country are derived by affiliation of the corresponding author

IMPACT FACTOR

Evolution impact factor



2022 impact factor not yet known.

MOST CITED ARTICLES IN 2022

Published between 2020 and 2021

107 citations in 2022

Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document

Lievens Y., Guckenberger M., Gomez D., Hoyer M., Iyengar P., Kindts I., Mendez Romero A., Nevens D., Palma D., Park C., Ricardi U., Scorsetti M., Yu J., Woodward W.A.

└ 2020

49 citations in 2022

Overview of artificial intelligence-based applications in radiotherapy: Recommendations for implementation and quality assurance

Vandewinckele L., Claessens M., Dinkla A., Brouwer C., Crijns W., Verellen D., van Elmpt W.

└ 2020

47 citations in 2022

Comparing deep learning-based auto-segmentation of organs at risk and clinical target volumes to expert inter-observer variability in radiotherapy planning

Wong J., Fong A., McVicar N., Smith S., Giambattista J., Wells D., Kolbeck C., Giambattista J., Gondara L., Alexander A.

└ 2020

These papers contribute to the 2022 Impact Factor.

MOST DOWNLOADED ARTICLES IN 2022

Regardless of publication date

14,964 downloads in 2022

The tubarial salivary glands: A potential new organ at risk for radiotherapy

Valstar M.H., de Bakker B.S., Steenbakkens R.J.H.M., de Jong K.H., Smit L.A., Klein Nulent T.J.W., van Es R.J.J., Hofland I., de Keizer B., Jasperse B., Balm A.J.M., van der Schaaf A., Langendijk J.A., Smeele L.E., Vogel W.V.

└ 2021

9,108 downloads in 2022

Delineation of the neck node levels for head and neck tumors: A 2013 update. DAHANCA, EORTC, HKNPCSG, NCIC CTG, NCRI, RTOG, TROG consensus guidelines

Grégoire, V., Ang, K., Budach, W., Grau, C., Hamoir, M., Langendijk, J., Lee, A., Le, Q., Maingon, P., Nutting, C., O'Sullivan, B., Porceddu, S., Lengele, B.

└ 2014

6,107 downloads in 2022

Radiation-induced neuropathy in cancer survivors

Delanian S., Lefaix J.-L., Pradat P.-F.

└ 2012

TOP ARTICLES BY SOCIAL MEDIA ATTENTION *

3,569 social media attention in 2022

The tubarial salivary glands: A potential new organ at risk for radiotherapy

Valstar M.H., de Bakker B.S., Steenbakkens R.J.H.M., de Jong K.H., Smit L.A., Klein Nulent T.J.W., van Es R.J.J., Hofland I., de Keizer B., Jasperse B., Balm A.J.M., van der Schaaf A., Langendijk J.A., Smeele L.E., Vogel W.V.

└ 2021

1,410 social media attention 2022

Is low dose radiation therapy a potential treatment for COVID-19 pneumonia?

Kirkby C, Mackenzie M.

└ 2020

293 social media attention 2022

Radiation therapy related cardiac disease risk in childhood cancer survivors: Updated dosimetry analysis from the childhood cancer survivor study

Suman Shrestha, James E Bates, Qi Liu, Susan A Smith, Kevin C Oeffinger, Eric J Chow, Aashish C Gupta, Constance A Owens, Louis S Constine, Bradford S Hoppe, Wendy M Leisenring, Ying Qiao, Rita E Weathers, Laurence E Court, Chelsea C Pinnix, Stephen F Kry, Daniel A Mulrooney, Gregory T Armstrong, Yutaka Yasui, Rebecca M Howell

└ 2021

*Social Media Attention is captured as a metric showing cumulative views, shares, likes comments etc. for the past 2 years, regardless of publication date.

2. Open access journals

ESTRO and Elsevier offer three open access journals that foster the dissemination of research in areas of importance to the Society's membership.

All members of ESTRO are eligible for a discounted fee to publish a paper in any of the three open access journals.

Authors of manuscripts submitted to *Radiotherapy and Oncology* that were not withheld for publication may be offered the opportunity to have their manuscript transferred to *ctRO*, *phiRO* or *tipsRO*. The decision on whether or not to go ahead with this transfer rests with the author of the article.



2.1 Clinical & Translational Radiation Oncology (ctRO)

Co-editors: Pierre Blanchard (Villejuif, France) and Daniel Zips (Berlin, Germany)


Clinical & Translational Radiation Oncology features research on all aspects of clinical and translational radiation oncology, particularly new developments in experimental radiobiology, clinical interventions and treatments. This includes imaging and biomarker studies with a clinical endpoint, as well as research results from data sciences, epidemiology and oncopolicy.

2021 Impact Factor: 4,739


2022 impact factor not known yet.

SUBMITTED PAPERS

Evolution of the number of articles submitted




Submitted articles by region



ACCEPTED PAPERS

Top 5 countries of accepted papers



MOST CITED ARTICLES IN 2022

Published between 2020 and 2021

33 citations in 2022

4D-MRI driven MR-guided online adaptive radiotherapy for abdominal stereotactic body radiation therapy on a high field MR-Linac: Implementation and initial clinical experience

Paulson E.S., Ahunbay E., Chen X., Mickevicius N.J., Chen G.-P., Schultz C., Erickson B., Straza M., Hall W.A., Li X.A.

└ 2020

28 citations in 2022

COVID-19: Global radiation oncology's targeted response for pandemic preparedness

Simcock R., Thomas T.V., Estes C., Filippi A.R., Katz M.A., Pereira I.J., Saeed H.

└ 2020

19 citations in 2022

The tumor microenvironment and radiotherapy response; a central role for cancer-associated fibroblasts

Ansems M., Span P.N.

└ 2020

These papers contribute to the 2022 Impact Factor.

MOST DOWNLOADED ARTICLES IN 2022

Regardless of publication date

4,802 downloads in 2022

Adaptive radiotherapy: The Elekta Unity MR-Linac concept

Winkel D., Bol G.H., Kroon P.S., van Asselen B., Hackett S.S., Werensteijn-Honingh A.M., Intven M.P.W., Eppinga W.S.C., Tijssen R.H.N., Kerkmeijer L.G.W., de Boer H.C.J., Mook S., Meijer G.J., Hes J., Willemsen-Bosman M., de Groot-van Breugel E.N., Jurgenliemk-Schulz I.M., Raaymakers B.W.

└ 2019

4,753 downloads in 2022

Dose constraints for whole breast radiation therapy based on the quality assessment of treatment plans in the randomised Danish breast cancer group (DBCG) HYPO trial

Thomsen M.S., Berg M., Zimmermann S., Lutz C.M., Makocki S., Jensen I., Hjelstuen M.H.B., Pensold S., Hasler M.P., Jensen M.-B., Offersen B.V.

└ 2021

3,907 downloads in 2022

Technical design and concept of a 0.35 T MR-Linac

Kluter S.

└ 2019

TOP ARTICLES BY SOCIAL MEDIA ATTENTION *

509 social media attention in 2022

COVID-19: Global radiation oncology's targeted response for pandemic preparedness

Simcock R., Thomas T.V., Estes C., Filippi A.R., Katz M.A., Pereira I.J., Saeed H.

└ 2020

230 social media attention in 2022

Availability of technology for managing cancer patients in the Southeast European (SEE) region

Dosanjh M, Ristova M, Gershan V, Georgieva P, Balin Kovacevic M, Bregu L, Coralic I, Djurovic T, Dosieva D, Foka Y, Fröbe A, Hatzioannou K, Hourdakos CJ, Kabashi Y, Kalev D, Kurtishi I, Litov L, Mezelxhiu B, Nestoroska Madjunarova S, Nikolova G, Skrk D, Smajlbegovic V, Smichkoska S, Stojkovski I, Strojjan P, Tecic Z, Tešanović D, Todorovic V, Valerianova Z.

└ 2022

113 social media attention in 2022

Low dose lung radiotherapy for COVID-19 pneumonia. The rationale for a cost-effective anti-inflammatory treatment

Pedro C Lara, Javier Burgos, David Macias

└ 2020

*Social Media Attention is captured as a metric showing cumulative views, shares, likes comments etc. for the past 2 years, regardless of publication date.

2.2 Physics & Imaging in Radiation Oncology (*phiRO*)


Co-editors: Ludvig Muren (Aarhus, Denmark) and Daniela Thorwarth (Tübingen, Germany)

Physics & Imaging in Radiation Oncology focuses on medical physics and imaging in radiation oncology. The journal publishes original research articles, reviews, technical notes, short communications and correspondence.


In July 2022 it was announced that *phiRO* will receive its first Impact Factor in 2023.

SUBMITTED PAPERS

Evolution of the number of articles submitted




Submitted articles by region



ACCEPTED PAPERS

Top 5 countries of accepted papers



MOST CITED ARTICLES IN 2022

Published between 2020 and 2021

36 citations in 2022

Clinical implementation of artificial intelligence-driven cone-beam computed tomography-guided online adaptive radiotherapy in the pelvic region

Sibolt P., Andersson L.M., Calmels L., Sjostrom D., Bjelkengren U., Geertsens P., Behrens C.F.

└ 2021

25 citations in 2022

Evaluation of measures for assessing time-saving of automatic organ-at-risk segmentation in radiotherapy

Vaassen F., Hazelaar C., Vaniqui A., Gooding M., van der Heyden B., Canters R., van Elmpt W.

└ 2020

20 citations in 2022

In vivo dosimetry in external beam photon radiotherapy: Requirements and future directions for research, development, and clinical practice

Olaciregui-Ruiz I., Beddar S., Greer P., Jornet N., McCurdy B., Paiva-Fonseca G., Mijnheer B., Verhaegen F.

└ 2020

These papers contribute to the 2022 Impact Factor.

MOST DOWNLOADED ARTICLES IN 2022

Regardless of publication date

2,891 downloads in 2022

Relationship between dosimetric leaf gap and dose calculation errors for high definition multi-leaf collimators in radiotherapy

Kim, J., Han, J., Hsia, A., Li, S., Xu, Z., Ryu, S.

└ 2018

2,876 downloads in 2022

Machine learning applications in radiation oncology

Field, M., Hardcastle, N., Jameson, M., Aherne, N., Holloway, L.

└ 2021

2,284 downloads in 2022

Clinical implementation of artificial intelligence-driven cone-beam computed tomography-guided online adaptive radiotherapy in the pelvic region

Sibolt, P., Andersson, L., Calmels, L., Sjöström, D., Bjelkengren, U., Geertsens, P., Behrens, C.

└ 2021

TOP ARTICLES BY SOCIAL MEDIA ATTENTION *

60 social media attention in 2022

Dose-volume-based evaluation of convolutional neural network-based auto-segmentation of thoracic organs at risk

Noémie Johnston, Jeffrey De Rycke, Yolande Lievens, Marc van Eijkeren, Jan Aelterman, Eva Vandersmissen, Stephan Ponte, Barbara Vanderstraeten

└ 2022

38 social media attention in 2022

Multi-center evaluation of dose conformity in stereotactic body radiotherapy

Lee J., Dean C., Patel R., Webster G., Eaton D.J.

└ 2019

32 social media attention in 2022

A single neural network for cone-beam computed tomography-based radiotherapy of head and neck, lung and breast cancer

Matteo Maspero, Antonetta C Houweling, Mark H F Savenije, Tristan C F van Heijst, Joost J C Verhoeff, Alexis N T J Kotte, Cornelis A T van den Berg

└ 2020

*Social Media Attention is captured as a metric showing cumulative views, shares, likes comments etc. for the past 2 years, regardless of publication date.


2.3 Technical Innovations & Patient Support in Radiation Oncology (*tipsRO*)

Editor-in-Chief: Michelle Leech (Dublin, Ireland)


Technical Innovations & Patient Support in Radiation Oncology offers radiation therapists, nurses and allied health professionals a forum for the publication of original research, case reports, practice development and health evaluation articles, reviews, short communications, technical notes and correspondence on topics including treatment planning and workflows, treatment delivery and verification, supportive care, psycho-oncology, education and training.

SUBMITTED PAPERS

Evolution of the number of articles submitted




Submitted articles by region



ACCEPTED PAPERS

Top 5 countries of accepted papers



Most cited articles in 2022

Published between 2020 and 2021

26 citations in 2022

Sarcopenia in cancer: Risking more than muscle loss

Anjanappa M., Corden M., Green A., Roberts D., Hoskin P., McWilliam A., Choudhury A.

└ 2020

17 citations in 2022

On-line adaptive MR guided radiotherapy for locally advanced pancreatic cancer: Clinical and dosimetric considerations

Placidi L., Romano A., Chiloiro G., Cusumano D., Boldrini L., Cellini F., Mattiucci G.C., Valentini V.

└ 2020

10 citations in 2022

Personalised treatment for older adults with cancer: The role of frailty assessment

O'Donovan A., Leech M.

└ 2020

These papers contribute to the 2021 Impact Factor.

MOST DOWNLOADED ARTICLES IN 2022

Regardless of publication date

5,602 downloads in 2022

Side effects in breast implants related to radiotherapy in breast cancer reconstructive surgery

Winkel de Faria Castro Fleury, E., Jasmin Huanca Bernal, K., Lucena Miranda Madeiro, A., Luis Cervera Ocana, W., Carlos Vendramini Fleury, J., Caobianco, L.

└ 2021

3,138 downloads in 2022

Surface guided radiation therapy: An international survey on current clinical practice

Batista V., Gober M., Moura F., Webster A., Oellers M., Ramtohl M., Kugele M. et al

└ 2022

1,571 downloads in 2022

Sarcopenia in cancer: Risking more than muscle loss

Anjanappa M., Corden M., Green A., Roberts D., Hoskin P., McWilliam A., Choudhury A.

└ 2020

TOP ARTICLES BY SOCIAL MEDIA ATTENTION *

347 social media attention in 2022

Analysis of dose using CBCT and synthetic CT during head and neck radiotherapy: A single centre feasibility study

Hay L.K., Paterson C., McLoone P., Miguel-Chumacero E., Valentine R., Currie S., Grose D., Schipani S., Wilson C., Nixon I., James A., Duffton A.

└ 2020

99 social media attention in 2022

Advanced practice: An ESTRO RTTC position paper

Duffton A., Devlin L., Tsang Y., Mast M., Leech M.

└ 2019

74 social media attention in 2022

Side effects in breast implants related to radiotherapy in breast cancer reconstructive surgery

Winkel de Faria Castro Fleury, E., Jasmin Huanca Bernal, K., Lucena Miranda Madeiro, A., Luis Cervera Ocana, W., Carlos Vendramini Fleury, J., Caobianco, L.

└ 2021

*Social Media Attention is captured as a metric showing cumulative views, shares, likes comments etc. for the past 2 years, regardless of publication date.

2.4 ESTRO Newsletter

The ESTRO Newsletter is published online on the ESTRO website. It provides a more informal space for members to read about the latest developments in radiation oncology and its community.

In each issue expert editors, selected from the membership, curate contents for themed disciplinary 'Corners' or report on specific topics. The newsletter typically includes information on the latest advances in research and practice, interviews with key opinion leaders, conference findings, a selection of research papers and paper reviews.

Find all articles on the ESTRO Website:

www.estro.org/About/Newsroom/Newsletter

Top five most read corners in 2022

1. Read it before your patients
2. Conferences
3. Young ESTRO
4. Brachytherapy
5. RTT

Top 5 most read articles in 2022

1. CONFERENCES CORNER

First Middle East Radiation Oncology Society (MESTRO) Conference 2022

Saad Alrashidi, Saudi Arabia

2. READ IT BEFORE YOUR PATIENTS

Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomised PREOPANC Trial

Eva Versteijne, Jacob L van Dam, Mustafa Suker, Quisette P Janssen, Karin Groothuis, Janine M Akkermans-Vogelaar, Marc G Besselink, Bert A Bonsing, Jeroen Buijsen, Olivier R Busch, Geert-Jan M Creemers, Ronald M van Dam, Ferry A L M Eskens et al, Dutch Pancreatic Cancer Group

└ J Clin Oncol. 2022 Jan 27

3. SOCIETY LIFE CORNER

ESTRO 2022 presidential and board elections - a word from the president

Ben Slotman

4. RTT CORNER

IGRT and its practice parameters

Debojoyti Dhar, India

5. YOUNG CORNER

Climate change, ESTRO and radiotherapy

Robert Chuter, UK

RESEARCH & DISSEMINATION

ESTRO is committed to supporting research relevant to its members. The scope of ESTRO involvement will vary with the research topic, the type of research activity, and the level of support requested.

The next pages explain the research activities with which ESTRO was involved in 2022.

E²-RADIATE

EORTC-ESTRO Radiation infrastructure for Europe

E²-RADIatE (EORTC 1811 study) is a platform that collects real-world data through prospective data registries in radiotherapy. Based on a collaboration between the European Organisation for Research and Treatment of Cancer (EORTC) and ESTRO, the project aims to be a pan-European infrastructure and a more efficient framework across the field of radiation oncology to generate robust data in cancer treatment and to further develop and integrate the discipline into therapeutic strategies.

E²-RADIatE comprises three innovative cohorts:

- └ **OligoCare** (EORTC 1822-RP)
- └ **ReCare** (EORTC 2011-RP).

OligoCare (EORTC 1822-RP)

OligoCare is a pragmatic observational cohort study to evaluate radical radiotherapy for patients with oligometastatic disease. The main objective is to identify patient, tumour, diagnostic and treatment characteristics impacting overall survival, when all cancer sites are treated with definitive local therapy.

OligoCare continues to recruit very well with 1,680 patients enrolled (cut-off 7 November 2022) in 44 institutions across Austria, Belgium, Czech Republic, France, Germany, Switzerland, Italy, The Netherlands, Spain, Slovenia and United Kingdom.

EPTN

European Particle Therapy Network

The European Particle Therapy Network (EPTN) is an ESTRO task force that was launched in 2017 as the number of clinical proton-therapy facilities in Europe was increasing rapidly, from five in 2009 to more than 30 in 2020. Most of these centres are hospital-based, and many are academic.

The eighth annual workshop was the first in-person meeting since the pandemic and so enjoyed wide representation, 35 participants came from 18 institutions in 11 European countries. The eighth EPTN workshop took place on 5 October 2022 at Particle Therapy Interuniversity Centre, Leuven, Belgium.

You can read about progress across the seven work packages, updates from European Union projects and other initiatives of interest to the network via this link: www.estro.org/Science/Activities/EPTN

EU-REST

European Union Radiation, Education, Staffing & Training

ESTRO joined forces with other associations and stakeholders to respond to the European Commission tender addressing Call HADEA/2022/OP/000: Service contract for analysis on workforce availability, education and training needs for the quality and safety of medical applications involving ionising radiation in the EU.

The resulting EU-REST project (European Union Radiation, Education, Staffing & Training) started on 1 September 2022 and will last until 31 August 2024. The project aims to provide an analysis of workforce availability, education, and training needs to ensure quality and safety aspects of medical applications involving ionising radiation in the EU, and foresees the development of staffing and education/training guidelines for key professional groups involved in ensuring radiation safety and quality of medical radiation applications in the EU member states.

MARLIN

Medical Applications of Radiation – Learning from Incidents and Near Misses

ESTRO joined forces with other associations and stakeholders to respond to the EU call for tender ENER/D3/2022-402 (ENER/LUX/2022/OP/0008): SAMIRA study on reporting and learning from patient-related incidents and near misses in radiotherapy, interventional cardiology, nuclear medicine and interventional and diagnostic radiology.

The resulting MARLIN project (Medical Applications of Radiation – Learning from Incidents and Near Misses) will run for 24 months and will support the implementation of Council Directive 2013/59/Euratom, specifically articles 63c–e and 104.5, by providing a comprehensive description of the current status of incident reporting.

It is important that the use of ionising radiation in the diagnosis and treatment of diseases is carefully monitored and measures are taken to minimise both the frequency and harm caused by accidental or unintended exposures to patients, according to the relevant articles of the Basic Safety Standards Directive (BSSD). The use of incident learning systems (ILSs), anonymous notification systems where incidents and near misses can be investigated and possible flaws in a process can be identified and rectified, will be studied with regard to their compliance with the BSSD and other regulatory requirements and their role in improving patient safety.

QuADRANT

Constant improvement in quality and safety of radiology, radiotherapy and nuclear medicine through clinical audit

The QuADRANT project “Constant improvement in quality and safety of radiology, radiotherapy and nuclear medicine through clinical audit” (project accepted under call for tenders N° ENER/D3/2019-231-2) started in January 2020 and concluded in December 2022. The QuADRANT project was led by the European Society of Radiology (ESR) together with the European Association of Nuclear Medicine (EANM) and ESTRO as consortium partners.

QuADRANT aims to promote constant improvement in quality and safety of radiology, radiotherapy and nuclear medicine through the implementation of clinical audit as part of Member States’ healthcare systems.

A paper highlighting the project - purpose, structure, findings - is submitted for publication in *Insights into Imaging*, a journal of ESR, insightsimaging.springeropen.com. This will be accompanied by an editorial in *Radiotherapy and Oncology*, the ESTRO journal.

GUIDELINES

The ESTRO Guidelines Committee coordinates the development and prioritisation of all ESTRO clinical and technical guidelines in the field of radiation oncology. It also contributes to multidisciplinary guidelines involving other professional oncology and medical physics societies both within Europe and internationally.

The following guidelines were developed under the auspices of the ESTRO Guidelines Committee in 2022 (click to access):

- └ GEC-ESTRO ACROP prostate brachytherapy guidelines
- └ European Society for Radiotherapy and Oncology Advisory Committee in Radiation Oncology Practice consensus recommendations on patient selection and dose and fractionation for external beam radiotherapy in early breast cancer

- └ Perspective paper about the joint EANM/SNMMI/ESTRO practice recommendations for the use of 2-[18F]FDG-PET/CT external beam radiation treatment planning in lung cancer
- └ ESTRO-ACROP guideline on surface guided radiation therapy
- └ ESTRO ACROP and SIOPE recommendations for myeloablative total body irradiation in children
- └ ESTRO ACROP guidelines for external beam radiotherapy of patients with complicated bone metastases
- └ ESTRO ACROP guidelines for external beam radiotherapy of patients with uncomplicated bone metastases
- └ GEC-ESTRO ACROP Recommendations on Calibration and Traceability of HE HDR-PDR Photon-Emitting Brachytherapy Sources at the Hospital Level
- └ Recommendations for Radiation Therapy in Oligometastatic Prostate Cancer: an ESTRO-ACROP Delphi consensus.

The following guidelines were endorsed by the ESTRO Guidelines Committee in 2022 (click to access):

- └ Joint EANM/SNMMI/ESTRO practice recommendations for the use of 2-[18F]FDG PET/CT external beam radiation treatment planning in lung cancer V1.0
- └ 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC)
- └ Radiation Therapy for Brain Metastases: An ASTRO Clinical Practice Guideline
- └ Radiation Therapy for IDH-Mutant Grade 2 and Grade 3 Diffuse Glioma: An ASTRO Clinical Practice Guideline
- └ Radiation Therapy for Endometrial Cancer: An American Society for Radiation Oncology Clinical Practice Guideline.

2

**ESTRO
SCHOOL**



The ESTRO School's mission is to:

- └ improve, professionalise and harmonise knowledge and practice in radiation oncology and associated professions in Europe and beyond.

To this end, the School:

- └ offers a wide range of live educational activities and online educational resources that enable professionals worldwide to acquire the most recent knowledge, skills and competencies in their daily practice.
- └ supports the implementation of the European Core Curricula with education and training programmes that target both young and senior radiation oncology professionals to deliver high-quality treatment and care to cancer patients.

In 2022, the ESTRO School demonstrated adaptability in a context still marked by travel and gathering restrictions due to Covid-19, and pursued its efforts to allow the community to keep track with education and knowledge.

In 2022, half of the teaching courses were held online. Several new formats have been developed to enrich the educational programme and make it accessible to everyone:



Pre-recorded lectures



Modules spreading the programme over several weeks, or condensed in a few days



Live online lectures



Live broadcasting of some courses with the faculty members teaching live at the ESTRO office (using the ONLINE PLUS format)

1. TEACHING COURSES


1.1 A RICH PALETTE ON OFFER

The portfolio of live teaching courses includes basic and more advanced courses that are targeted at the various radiation oncology professions.

The topics cover the main areas of radiation oncology and multidisciplinary cancer treatment courses on:

- └ Radiotherapy treatment planning and delivery:
external beam and brachytherapy
- └ Multimodal cancer treatment, in general and also
site-specific treatment
- └ Imaging
- └ Best practice
- └ Research
- └ Biological aspects of radiation oncology.


1.2 2022 AT A GLANCE




Top 5 most attended courses

- └ 145 participants
Basic Clinical Radiobiology
- └ 124 participants
Implementation and Practice of Image-guided Stereotactic Body Radiotherapy
- └ 107 participants
Physics for Modern Radiotherapy (a Joint Course for Clinicians and Physicists)
- └ 105 participants
Particle Therapy
- └ 91 participants
Image-Guided and Adaptive Radiotherapy


Top 10 countries - Courses online and onsite



Breakdown participants per continent - Courses online and onsite




Growth in the number of courses and participants over the years



1.3 PRE MEETING COURSES

The first day of the annual congress is always dedicated to teaching courses. Five pre-meeting courses took place onsite in Copenhagen on 6 May 2022 at the occasion of ESTRO 2022.

Number of participants per pre-meeting course



2. E-LEARNING

2.1 Training in delineation

An accurate and precise anatomical contouring of target volume and OaRs* is of utmost importance in radiotherapy. FALCON**, ESTRO's contouring programme, allows radiation oncology professionals to improve their contouring skills.

In using the FALCON EduCase software, trainees can compare their individual contours with those made by delineation experts and visualise the ESTRO international guidelines.

* Organs at Risk
**Fellowship in Anatomic deLineation and CONtourings

FALCON is integrated into the whole portfolio of the educational ESTRO activities:




Live courses



Workshops at ESTRO meetings



Online virtual workshops




Support services
for clinical trials
and development of
guidelines



Delineation workshops for other societies
(IAEA, national societies or other societies active in the field of oncology)


2.2 Online delineation workshops

Top 3 countries



Geographic distribution of participants

at online blended FALCON workshops



- 58% Europe
- 28.5% Oceania
- 7.2% Asia
- 2.8% Middle East
- 2% North America
- 1% South America
- 0.5% Africa




471
Participants



13
Online
delineation
workshops


Evolution of number of participants

at online delineation workshops





2.3 Delineation workshops at the ESTRO annual congress

In addition to the pre-meeting courses, ESTRO offers hands-on delineation workshops in the framework of the annual congress.



Number of participants per contouring workshop:






MEMBERSHIP & PARTNERSHIPS

With more than 8,000 radiation oncology professionals from across the world, the ESTRO membership is the heart of our society.

ESTRO contributes to the day-to-day practice and career advancement of oncology professionals through the dissemination of the latest trends in practice, research findings and knowledge.



MEMBERSHIP

ESTRO offers several levels of membership, with benefits tailored to the needs of each member and their degree of involvement within the society.

The full range of ESTRO membership benefits includes:



Belonging to a community of more than 8,000 radiation oncology professionals



Reduced fees for attending ESTRO congresses, workshops and courses



Networking opportunities



Online access to scientific material, including event webcasts and delineation cases



Subscription to *Radiotherapy and Oncology*, the society's journal, and reduced members' fees for publishing in the ESTRO open access journals



Eligibility for mentorship programme, grants, awards, ESTRO faculties and governance positions




Voting rights at the ESTRO General Assembly


1. Profile of ESTRO Members


8,297
 Members


5
 Continents


112
 Countries


Breakdown of ESTRO members by speciality




The ESTRO community extends far beyond these professional radiation oncology disciplines, taking in a wide range of other professions.

- This includes professionals from:
- └ other medical fields, such as surgeons, radiologists, medical oncologists, gynaecologists and urologists
 - └ and non-medical fields, such as public affairs specialists.


Top 10 countries



Geographical distribution



Evolution of membership



After two years of pandemic, the ESTRO membership increased again in 2022 to reach a record with more than 8,000 members.

2. A wide range of membership categories

54.5%
INDIVIDUAL MEMBERS
(4,526)

31.2% FULL (2,590)


- 30.2% Active (2,504)
- 0.9% Supporting Ambassador (76)
- 0.1% Emeritus (10)

23.3% ASSOCIATE (1,936)

- 16.9% Affiliate (1,400)
- 6.4% In-Training (527)
- 0.1% Honorary (9)

21.6%
INSTITUTIONAL MEMBERS
(1,795)

51 Institutes



15.4%
JOINT MEMBERS
(1,246)

- 9% Joint (746)
- 6.4% Joint In-Training (527)

6%
RTT ALLIANCE MEMBERS
(494)

24 National societies

2.5%
CORPORATE MEMBERS
(206)

33 Companies

3. Membership categories under the spotlight

1. Institutional membership

The institutional membership is designed for centres aiming to support their oncology teams in their professional development. It also fosters interdisciplinarity and multidisciplinary within the departments.

With this category, centres can purchase individual memberships on behalf of their employees, with very attractive conditions.

Centres also benefit from an increased visibility with:

- └ A dedicated institutional webpage on the ESTRO website
- └ A complimentary networking space in the Communities Pavilion during the annual congress
- └ Free online job postings
- └ An “ESTRO institutional member” logo.



70

Institutes in total
List available in the Annex



1,795

Professionals supported through this membership category



16

New institutional members in 2022

New institutional members in 2022:

- └ Basel, St. Claraspital
- └ Basel, Universitäts Spital Basel (USB)
- └ Bellinzona, Ospedale San Giovanni (EOC)
- └ Bern, Inselspital (Universitäts Spital Bern)
- └ Fribourg, Hôpital Cantonal (HFR)
- └ Genève, Hôpitaux Universitaires (HUG)
- └ Genolier, Clinique de Genolier
- └ La Chaux-de-Fonds, Réseau Hospitalier Neuchâtelois (RHNe)
- └ Lausanne, Clinique La Source
- └ Lausanne, Hirslanden Clinique de Bois-Cerf
- └ Lugano, Gruppo Ospedaliero Moncucco
- └ Paul Scherrer Institut (PSI)
- └ Radio-Onkologie-Zentrum KSA-KSB
- └ Sion, Hopital du Valais
- └ Winterthur, Kantonsspital Winterthur (KSW)
- └ Zürich, Stadtspital Triemli.

2. Supporting ambassador membership



145

Individuals signed up as supporting ambassadors.

This membership category is reserved for professionals in the field of radiation oncology who are strongly committed to supporting the ESTRO activities in the enhancement of the radiotherapy community.

3. In-Training members and members up to 40 years old

It is essential for ESTRO to invest and connect with the next generation of healthcare professionals and decision-makers.

To this end, ESTRO consolidates its collaboration with European societies representing the new generation of radiation oncology professionals and encourages them to join the society.

ESTRO In-Training members are professionals in the field of radiation oncology who are in training or full time PhD and have obtained their diploma within the last 10 years.

Illustrations of the involvement of the new generation of professionals in the ESTRO community

The Young Corner

Dedicated section in the ESTRO newsletter with news from young national societies and young members sharing their experience through meetings, travel grant reports, etc.


The Young Track

Full-day programme held during ESTRO's annual congress, which focuses specifically on topics of interest to young professionals.


Opinion Panel

Online, bi-monthly questionnaire where panelists share their opinion on the yESTRO Committee activities and take their first step within the ESTRO community.

Breakdown of In-Training members



Evolution of In-Training members



3,810 Young ESTRO members (In training and members up to 40 years old) in the society in 2022

4. Joint membership

This category can be granted to individual members who benefit from a joint membership agreement, signed on a case-by-case basis between ESTRO and a non-European society or a young national society active in the field of radiation oncology. In 2022, ESTRO counted 1,276 joint members.

5. Corporate members

With the ESTRO Corporate membership, the industry has privileged access to the global radiotherapy and oncology community. Gold Corporate members are invited to engage with ESTRO and its community via the ESTRO Advisory Corporate Council. As council members, they have the opportunity to give their views on the clinical practice in radiation oncology and support the long-term objectives of the society.

Corporate members in 2022



33 corporate members:

- 13 gold members
- 20 regular members

RTT Alliance

The objective of the RTT Alliance, initiated by ESTRO a few years ago, is to strengthen the collaboration with national societies representing RTTs, at both European and international level.



24
National societies members of the
RTT Alliance

In 2022, one additional national societies joined the RTT Alliance:

- └ Radiotherapists' Association of Tanzania (RAOTA).

Full list available in the Annex.

MoUs

Memoranda of understanding (MoUs) on science, education and membership are key agreements that enable ESTRO to establish new collaborations and nurture existing ones with other societies in the field of oncology.


In 2022, ESTRO signed MoUs with the following national and international societies:

- └ Spanish Society of Medical Physics (SEFM in training)
- └ International Atomic Energy Agency (IAEA)
- └ European Association for Dermato-Oncology (EADO)
- └ Paediatric Radiation Oncology Society (PROS)
- └ Royal Australian and New Zealand College of Radiologists (RANZCR).

Additional MoUs are being drafted and renewed in 2023.



ESTRO CANCER FOUNDATION (ECF)



The ESTRO Cancer Foundation (ECF) continues its efforts to foster the outreach of radiotherapy at the European level, especially by implementing the Value Based HealthCare (VBHC) project and UpLung, a project initiated in 2020. Both initiatives aim to improve the access of patients to high-quality radiotherapy treatment.

Two projects are currently ongoing under the auspices of the ECF.

VBHC

Value Based Health Care

The Value Based Health Care (VBHC) project is an ESTRO/ECF - HERO Project. The landscape of innovative interventions in radiotherapy is diverse and complex in terms of technologies, techniques and treatment schemes.

The project will aim to provide a better view and agreement on different types and categorisation of innovative interventions in radiation oncology. This is the first necessary step to support policy-making and reimbursement schemes, allowing for optimisation of patient access to radiotherapy.

Supported by a grant from Elekta and Varian, the project will run for three years.

UpLung

Utilisation of radiotherapy for Lung cancer in Europe

Utilisation of radiotherapy for Lung cancer in Europe (UpLung) is an ESTRO/ECF-HERO project. This research initiative was launched in November 2020 aiming to explore the challenges to the uptake of radiotherapy for lung cancer patients in Europe.

Supported by a grant from AstraZeneca, this project will use qualitative and quantitative research to characterise the radiotherapy access landscape in Europe and develop policy recommendations to improve patient outcomes by closing gaps in access to high-quality radiotherapy.

5

FINANCIAL REPORT



1. Treasurer's report for 2021

Dear Friends,

In last year's report, being carefully optimistic, I quoted Nietzsche ("was mich nicht umbringt, macht mich stärker"*). This year, we can claim with a reasonable degree of confidence that indeed we managed the turbulent years with minimal damage. The combined efforts of you as members and the ESTRO office, showing with a large amount of flexibility and adaptation, safe-guarded our financial stability. We are not out of the woods yet, but we can start making plans for the future again. And indeed, the new governance structure and the outcome of the recent strategy retreat show promise with new building blocks for a strong, solid and future-proof Society.

If we look at 2021 in detail: the auditors provided an unqualified opinion and showed a total net result of €44k including financial and extraordinary charges. While the total revenue generated by the ESTRO activities mounted to €6.02M, the total of expenditures represented an amount of €5.94M. In short, a clear break-even.

Concerning 2022, as usual, the accounts are being audited at the time of writing and the final result will be presented for approval at the General Assembly on 15 May 2023. As mentioned earlier we managed to face the challenges of the last years, yet we still need to monitor the operational costs carefully. This approach paid off: as the intermediate forecast (presented in May 2022) indicated that we would not meet the approved budget, we can now anticipate a final result that matches the original budget. Revenues and expenses at the end of 2022 are estimated at €8.08M and €7.55 respectively, with an expected net result of €450k (including the financial and extraordinary results).

The ESTRO Portfolio (a defensive, Social Responsible (ethical) Investment profile, managing the cash reserves) was of course impacted by the pandemic and the war in Ukraine (with a negative return in 2022, which seems to have recovered at the start 2023). The total reserve shows a capital of €2.03M at the end of January 2023, which is not too bad considering the general economic situation.

To close this report, I would like to thank you all for your commitment to ESTRO and our industry partners for the continuous support. All things considered, together we seem to be managing this crisis quite well. As always, please feel free to contact me anytime with questions or concerns regarding ESTRO's financial situation, and of course, I look forward to meeting you all, in person, at our annual meeting in Vienna.

Warm regards, and as always, think pink,

Dirk Verellen
ESTRO Treasurer

**What does not kill me, makes me stronger*

2. ESTRO audited accounts 2021

Everything in KEUR except mentioned otherwise

The figures presented in this report were approved at the ESTRO general assembly on 9 May 2022.


In 2021, operating revenues rose to almost €6.018 million, led by registrations at meetings and courses and exhibition subscriptions.

The financial incomes represented an amount of €3,000 while the financial charges, including bank charges and credit card commissions, represented €41,000.

With operating expenses of €5,936 million the net impact of income and expenditure is a net result of €44,000.


Net Result (Net Profit) €44,000

Revenue




ESTRO 2021	3,364
WCB 2021	159
ESTRO School	709
Workshops	100
Memberships	766
Elsevier Royalties/Comm.	653
Other Revenues	267
TOTAL	6,018

Expenditure




ESTRO 2021	1,843
WCB 2021	38
ESTRO School	391
Workshops	68
Memberships	13
Governance (Commit & Council)	98
Other Activity Costs	12
Employment Costs	2,190
General & Administration	680
General IT (incl. Website,..)	164
Communication/Marketing	19
Elsevier Charges	420
TOTAL	5,936

Financial result



Financial Incomes	3
Bank & Credit card charges	-40
Other Financial charges	-1
TOTAL	-38

3. Cumulated result 2008 - 2022



6

ANNEX



1. Governance & Constituent Bodies

Board of Directors

Ben Slotman - Amsterdam, The Netherlands
ESTRO President

Anna Kirby - London, UK
ESTRO President-Elect

Umberto Ricardi - Turin, Italy
ESTRO Past-President

Dirk Verellen - Antwerp, Belgium
ESTRO Treasurer

Elizabeth Forde - Dublin, Ireland
ESTRO Board Member, Membership Officer

Ben Heijmen - Rotterdam, The Netherlands
ESTRO Board Member

Esther Troost - Dresden, Germany
ESTRO Board Member

Kari Tanderup - Aarhus, Denmark
ESTRO Board Member

Marc Vooijs - Maastricht, The Netherlands
ESTRO Board Member (before the General Assembly)

Matthias Guckenberger - Zurich, Switzerland
ESTRO Board Member

Nuria Jornet - Barcelona, Spain
ESTRO Board Member

Michael Baumann - Heidelberg, Germany
*Non-voting Director
Radiotherapy and Oncology Editor-in-Chief*

Jesper Eriksen - Aarhus, Denmark
*Non-voting Director
Education Council Director*

Updates after the General Assembly

Anna Kirby - London, UK
ESTRO President

Ben Slotman - Amsterdam, The Netherlands
ESTRO Past-President

Matthias Guckenberger - Zurich, Switzerland
ESTRO President-Elect

Umberto Ricardi - Turin, Italy
Interim Board Member

Kerstin Borgmann - Hamburg, Germany
ESTRO Board Member

Executive Council

Ben Slotman - Amsterdam, The Netherlands
ESTRO President

Anna Kirby - London, UK
ESTRO President-Elect

Umberto Ricardi - Turin, Italy
ESTRO Past-President (before the General Assembly)

Dirk Verellen - Antwerp, Belgium
ESTRO Treasurer

Alessandro Cortese - Brussels, Belgium
ESTRO CEO

Updates after the General Assembly

Anna Kirby - London, UK
ESTRO President

Ben Slotman - Amsterdam, The Netherlands
ESTRO Past-President

Matthias Guckenberger - Zurich, Switzerland
ESTRO President-Elect

Nominating Council

Ben Slotman - Amsterdam, The Netherlands
ESTRO President

Anna Kirby - London, UK
ESTRO President-Elect

Umberto Ricardi - Turin, Italy
ESTRO Past-President (before the General Assembly)

Updates after the General Assembly

Anna Kirby - London, UK
ESTRO President

Ben Slotman - Amsterdam, The Netherlands
ESTRO Past-President

Matthias Guckenberger - Zurich, Switzerland
ESTRO President-Elect

Scientific Council

Ben Slotman - Amsterdam, The Netherlands
ESTRO President

Anna Kirby - London, UK
ESTRO President-Elect

Umberto Ricardi - Turin, Italy
ESTRO Past-President (before the General Assembly)

Michael Baumann - Heidelberg, Germany
Radiotherapy and Oncology Editor-in-Chief

Pierre Blanchard, Villejuif, France
ctRO Editor-in-Chief

Ludvig Muren, Aarhus, Denmark
phiRO Editor-in-Chief

Michelle Leech, Dublin, Ireland
tipsRO Editor-in-Chief

Jesper Eriksen - Aarhus, Denmark
Education Council Director

Catharine Clark - Guildford, UK
Physics Committee Chair

Fiona McDonald - London, United Kingdom
Guidelines Committee Chair

Heidi Lyng - Oslo, Norway
Radiobiology committee Chair

Ina Jurgenliemk-Schulz - Utrecht, The Netherlands
GEC-ESTRO committee Chair (before the General Assembly)

Karin Haustermans - Leuven, Belgium
Clinical Committee Chair

Philipp Scherer - Salzburg, Austria
RTT committee Chair

Steven Petit - Rotterdam, The Netherlands
Young Committee Member

Ben Heijmen - Rotterdam, The Netherlands
ESTRO Board Representative

Marc Vooijs - Maastricht, The Netherlands
ESTRO Board Representative (before the General Assembly)

Matthias Guckenberger - Zurich, Switzerland
ESTRO Board Representative

Ajay Aggarwal - London, UK
HERO Co-Chair

Yolande Lievens - Ghent, Belgium
HERO Co-Chair

Damien Weber - Villigen, Switzerland
EPTN task force Co-Chair

Updates after the General Assembly

Anna Kirby - London, UK
ESTRO President

Ben Slotman - Amsterdam, The Netherlands

ESTRO Past-President

Matthias Guckenberger - Zurich, Switzerland
ESTRO President-Elect

Vratislav Strnad - Erlangen, Germany
GEC-ESTRO committee Chair

Kerstin Borgmann - Hamburg, Germany
ESTRO Board Representative

Education Council

Jesper Eriksen - Aarhus, Denmark
Chair & Leader Live Programme

Marie-Catherine Vozenin - Lausanne, Switzerland
Leader Mobility Programme

Michelle Leech
Leader Blended Learning Programme, Dublin, Ireland

Aileen Duffton - Glasgow, UK

Ben Heijmen - Rotterdam, The Netherlands

Kari Tanderup - Aarhus, Denmark

Nuria Jornet - Barcelona, Spain

Bradley Pieters - Amsterdam, The Netherlands
GEC

Ben Slotman - Amsterdam, The Netherlands

Anna Kirby - London, UK

Matthias Guckenberger - Zurich, Switzerland

John Cacicedo - Bilbao, Spain

Katherine Wakeham - Vienna, Austria

Amanda Webster, London, UK
Young Committee Observer

Jolien Heukelom - Maastricht, The Netherlands
Young Committee Observer

Stakeholders Council

Ben Slotman - Amsterdam, The Netherlands
ESTRO President

Anna Kirby - London, UK
ESTRO President-Elect

Umberto Ricardi - Turin, Italy
ESTRO Past-President (before the General Assembly)

Elizabeth Forde - Dublin, Ireland
ESTRO Board Member, Membership Officer

Dirk Verellen, Antwerp, Belgium
ESTRO Board Representative

Nuria Jornet - Barcelona, Spain
ESTRO Board Representative

Marc Vooijs - Maastricht, The Netherlands
ESTRO Board Representative (before the General Assembly)

Joanna Kazmierska, Poznan, Poland
Patient Advisory Group liaison

Barbara Alicja Jereczek-Fossa - Milan, Italy
National Societies Committee Representative

Mary Coffey - Dublin, Ireland
Radiation Oncology Safety and Quality Committee (ROSQ) Representative

Updates after the General Assembly

Anna Kirby - London, UK
ESTRO President

Ben Slotman - Amsterdam, The Netherlands
ESTRO Past-President

Matthias Guckenberger - Zurich, Switzerland
ESTRO President-Elect

Clinical Committee

Karin Haustermans - Leuven, Belgium
Chair

Antonietta Gambacorta - Rome, Italy

Corinne Faivre-Finn - Manchester, United Kindgom

Dorota Gabrys - Gliwice, Poland

Eric Deutsch - Villejuif, Paris, France

Esther Troost - Dresden, Germany

Florence Huguet - Paris, France

Hans Langendijk - Groningen, The Netherlands

Lorenzo Livi - Florence, Italy

Marianne Nordmark - Aarhus, Denmark

Pedro Lara - Las Palmas de Gran Canaria, Spain

Peter Hoskin - Northwood and Manchester, UK

Martin-Immanuel Bittner, Cambridge, UK
Young Committee Observer

GEC-ESTRO Committee

Ina Jürgenliemk-Schulz - Utrecht, The Netherlands
Chair

Vratislav Strnad - Erlangen, Germany
Chair-Elect

Bradley Pieters - Amsterdam, The Netherlands
Past-Chair

Marisol De Brabandere
Secretary

Alexandra Stewart - Guildford, UK
Gastro-Intestinal Chair

Frank-André Siebert - Kiel, Germany
BRAPHYQS Chair

Jean-Michel Hannoun-Levi - Nice, France
Breast Chair

Kari Tanderup - Aarhus, Denmark
Gynaecology Chair

Luca Tagliaferri - Rome, Italy
Head and Neck and Skin Chair

Peter Hoskin - Northwood and Manchester, UK
Urology Chair

Peter Niehoff - Offenbach, Germany
Brachy-HERO Chair

Li Tee Tan - Cambridge, UK
Observer – GEC-ESTRO Representative in the National Societies Committee

Csaba Polgár - Budapest, Hungary

Cyrus Chargari - Villejuif, France
Young Committee Observer

Updates after the General Assembly

Vratislav Strnad - Erlangen, Germany
Chair

Frank-André Siebert - Kiel, Germany
Chair-Elect

Ina Jürgenliemk-Schulz - Utrecht, The Netherlands
Past-Chair

Physics Committee

Catharine Clark - Guildford, UK
Chair

Daniela Thorwarth - Tübingen, Germany
Secretary

Christian Richter - Dresden, Germany

Coen Hurkmans - Eindhoven, The Netherlands

Cristina Garibaldi - Milan, Italy

Frank-André Siebert - Kiel, Germany
GEC-ESTRO BRAPHYQS Chair

Marianne Aznar - Manchester, UK

Nuria Jornet - Barcelona, Spain

Victor Hernandez - Tarragona, Spain

Wouter van Elmpt - Maastricht, The Netherlands

Ben Heijmen - Rotterdam, The Netherlands
ESTRO Board Representative

Dirk Verellen - Antwerp, Belgium
ESTRO Board Representative

Dietmar Georg - Vienna, Austria
Observer - Green Journal Physics Editor & EPTN

Ludvig Muren - Aarhus, Denmark
Observer - phiRO Editor-in-Chief

Jenny Bertholet - London, UK
Young Committee Observer

Kathrine Røe Redalen - Trondheim, Norway
Young Committee Observer

Updates after the General Assembly

Charlotte Robert - Villejuif, France

Radiobiology Committee

Heidi Lyng - Oslo, Norway
Chair

Anthony Chalmers - Glasgow, UK

Brita Singers Sørensen - Aarhus, Denmark

Ester Hammond - Oxford, UK

François Paris - Nantes, France

Kerstin Borgmann - Hamburg, Germany

Laure Marignol - Dublin, Ireland

Marc Vooijs - Maastricht, The Netherlands

Monica Mangoni - Florence, Italy

Bartłomiej Tomasik - Gdansk, Poland
Young Committee Observer

Ludwig Dubois - Maastricht, The Netherlands
Young Committee Observer

RTT Committee

Philipp Scherer - Salzburg, Austria
Chair

Annette Schouboe - Aarhus, Denmark

Bernd Wisgrill - Vienna, Austria

Ilija Curic - Belgrade, Serbia

Ingrid Kristensen - Lund, Sweden

Isabel Lobato - Evora, Portugal

Ludwig Van den Berghe - Ghent, Belgium

Maddalena Rossi, Amsterdam, The Netherlands
(before the General Assembly)

Maeve Kearney - Dublin, Ireland

Márton Vékás - Somogy, Hungary

Monica Buijs - Amsterdam, The Netherlands

Yat Man Tsang - Toronto, Canada

Rita Simoes - London UK - Observer

Sophie Boisbouvier - Lyon, France
Observer

Elizabeth Forde - Dublin, Ireland
ESTRO Board Representative

Sophie Perryck - Zurich, Switzerland
Young Committee Observer

Updates after the General Assembly

Rita Simoes - London UK
Full member

Sophie Boisbouvier - Lyon, France
Full member

Siret Kivistik - Tartu, Estonia
Observer

Paolo Brossa - Turin, Italy
Observer

Young Committee

Pierfrancesco Franco - Novara, Italy
Chair

Amanda Webster - London, UK

Cyrus Chargari - Villejuif, France

Daan Nevens - Antwerp, Belgium

Jenny Bertholet - Bern, Switzerland

Jolien Heukelom - Rotterdam, The Netherlands

Kathrine Røe Redalen- Trondheim, Norway

Ludwig Dubois, Maastricht, The Netherlands

Martin-Immanuel Bittner - Oxford, UK

Sophie Perrick - Zurich, Switzerland

Steven Petit - Rotterdam, The Netherland

Updates after the General Assembly

Steven Petit - Rotterdam, The Netherland
Chair

Guidelines Committee

Fiona McDonald - London, UK
Chair

Jesper Grau Eriksen - Aarhus, Denmark
Education Council representative

Coen Hurkmans - Eindhoven, The Netherlands
Physics Committee representative

Jeroen Van de Kamer, Amsterdam, The Netherlands
Physics Committee representative

Antonietta Gambacorta, Rome, Italy
Clinical Committee representative

Peter Hoskin, Northwood, UK
Clinical Committee representative

Laure Marignol, Dublin, Ireland
Radiobiology Committee representative

Rob Coppes, Groningen, The Netherlands
Radiobiology Committee representative

Philip Scherer, Salzburg, Austria
RTT Committee representative

Yat Man Tsang, Toronto, Canada
RTT Committee representative

Luca Tagliaferri, Rome, Italy
GEC-ESTRO Committee representative

Panagiotis Papagiannis, Athens, Greece
GEC-ESTRO Committee representative

Pierfrancesco Franco, Turin, Italy
Young Committee Observer

Barbara Jereczek-Fossa, Milan, Italy
National Societies Committee Observer

National societies Committee

Barbara Alicja Jereczek-Fossa - Milan, Italy
Chair

Nuria Jornet - Barcelona, Spain
Education Council & Physics Committee Representative

Esther Troost - Dresden, Germany
Clinical Committee Representative (before the General Assembly)

Cristina Garibaldi - Milan, Italy
Physics Committee Representative

Li Tee Tan - Cambridge, UK
GEC-ESTRO Committee Representative

Bartosz Bak - Poznan, Poland
RTT Committee Representative (before the General Assembly)

Ludwig van den Berghe - Ghent, Belgium
RTT Committee Representative

Maia Dzhugashvili - Murcia, Spain
Board-nominated Representative

Daan Nevens – Antwerp, Belgium
Young Committee Representative

Pierfrancesco Franco - Turin, Italy
Young Committee Representative

Updates after the General Assembly

Dorota Gabrys - Gliwice, Poland
Clinical Committee Representative

Pedro Lara - Las Palmas de Gran Canaria, Spain
Clinical Committee Representative

Christian Richter - Dresden, Germany
Physics Committee Representatie

Banu Atalar - Istanbul, Turkey
Full member

Edward Farrugia Wismayer - Msida, Malta
Full member

Radiation Oncology Safety and Quality (ROSQ) Committee

Mary Coffey - Dublin, Ireland
Chair

Amanda Caissie - Halifax, Canada

Anita O'Donovan - Dublin, Ireland

Brian Liszewski - Ontario, Canada

Dirk Verellen - Antwerp, Belgium

Geoff Delaney - Sydney, Australia

Maeve Kearney - Dublin, Ireland

Michael Milosovic - Toronto, Canada

Petra Reijnders-Thijssen - Maastricht, The Netherlands

Philippe Maingon - Paris, France

Velimir Karadza - Zagreb, Croatia

Sophie Perryck - Zurich, Switzerland
Young Committee Observer

Task Force: European Particle Therapy Network (EPTN)

Organisers:

Cai Grau - Aarhus, Denmark

Damien Weber - Villigen, Switzerland

Dietmar Georg - Vienna, Austria

Work Packages (WP): WP1 - Clinical coordinators

Hans Langendijk - Groningen, The Netherlands
Leader

Daniel Zips - Tuebingen, Germany

Esther Troost - Dresden, Germany

Jacques Balosso - Grenoble, France

Karin Hausterman - Leuven, Belgium

Roberto Orecchia - Milano, Italy

WP2 Dose assessment, quality assurance, dummy runs, technology inventory

Oliver Jäckel - Heidelberg, Germany

Sairos Safai - Villigen, Switzerland

Stefano Lorentini - Trento, Italy

WP3 Education

Morten Høyer - Aarhus, Denmark

Marco Schwarz - Trento, Italy

WP4 Image guidance in particle therapy

Aswin Hoffmann - Dresden, Germany

Alessandra Bolsi - Villigen, Switzerland

WP5 TPS in particle therapy

Håkan Nyström - Uppsala, Sweden

Tony Lomax - Villigen, Switzerland

WP6 Radiobiology, RBE

Manjit Dosanjh - Geneva, Switzerland

Bleddyn Jones - Oxford, UK

Jörg Pawelke - Dresden, Germany

Martin Pruschy - Zurich, Switzerland

Brita S. Sørensen - Aarhus, Denmark

WP7 Health economy

Yolande Lievens - Ghent, Belgium

Klaus Nagels - Bayreuth, Germany

HERO Group

Ajay Aggarwal - London, UK
Co-chair

Yolande Lievens - Ghent, Belgium
Co-chair

Cai Grau, Aarhus, Denmark

Josep Borras - Bracelona, Spain

Judith van Loon - Maastricht, The Netherlands

Julietta Corral - Bracelona, Spain

Lionel Perrier - Lyon, France

Mary Coffey - Dublin, Ireland

Peter Dunscombe † - Alberta, Canada

Noémie Defourny - Manchester, UK

2. Staff

CEO

Alessandro Cortese

Society affairs & executive office

Chiara Gasparotto
Deputy CEO

Evelyn Chimfwembe
Manager Society Affairs & Research Projects

Simone De Ioanna
Governance & Education Project Manager

Charline Muco
Society Affairs Coordinator

Education

Laura La Porta
Senior Manager Education

Agnès Delmas
Committees & Education Project Manager

Karolina Kowalska
Committees & Education Project Manager

Andrea Collavini
Governance & Education Project Manager

Miika Palmu
Senior Project Manager

Science

Eralda Azizaj
Senior Manager Science

Jessica Pledge
Scientific Programme Manager

Jonas Johansen
Coordinator Scientific & EU projects

Membership & partnerships

Valerie Cremades
Membership & Partnerships Manager

Marketing & Events

Tania Bellon Almodovar
Senior Manager Marketing & Events

Agostino Barrasso
Congress Manager

Laura Conde Tumbarell
Marketing & Communication Coordinator

Céline Dechamps
Project Manager Workshops

Corporate relationships

Hande Van Gestel
Exhibition Project Manager

Registration & administration

Sigrid Jacobs-Peeters
Programmes Supervisor

Rebecca Hansmann
Logistics Administrator

Claire Thomas
Programmes Administrator

Finance

Arnaud Ponsart
Senior Finance Manager

Gurkan Ulusoy
Accounting Coordinator

Dina Ardiana
Finance & HR Coordinator

Human Resources

Nathalie Cnops
Senior HR Manager

IT

Mickael Bohland
IT Development Manager

Benjamin Corroy
IT Support Officer

ESTRO Cancer Foundation - ECF

Arta Leci
ECF Project Manager

Consultants

Mieke Akkers
Education Project Manager

Jill Barnard
Operational Communications

Daneel Bogaerts
Graphic Design

Cécile Hardon-Villard
Strategic Communications

Essi Sarto
Scientific Programme Coordinator

3. Corporate Members

Gold corporate members

ACCURAY

BOSTON SCIENTIFIC

CIVCO RADIOTHERAPY

ELEKTA INSTRUMENT AB

IBA

MIM SOFTWARE INC

ORFIT INDUSTRIES

PHILIPS

QFIX

S.I.T. - SORDINA IORT TECHNOLOGIES S.P.A

SUN NUCLEAR CORPORATION

VARIAN, A SIEMENS HEALTHINEERS COMPANY

VIEWRAY

Corporate members

Adaptiiv Medical Technologies Inc.

AQUILAB

AstraZeneca PLC

BRAINLAB

Carl Zeiss Meditec AG

C-RAD POSITIONING AB

INTRAOP

KLARITY MEDICAL & EQUIPMENT CO., Ltd

LYZE MEDICAL TECHNOLOGIES

MACROMEDICS

MICROPOS MEDICAL

NANOVI A/S

PALETTE LIFE SCIENCES

PMB-ALCEN

PTW Freiburg

RAD TECHNOLOGY MEDICAL SYSTEMS

RADFORMATION

RaySearch Laboratories AB (Publ)

SCANDIDOS AB

VISION RT Ltd

4. Joint members

Joint In-Training radiation oncology national societies

Associazione Italiana di Radioterapia Oncologica Giovani (Young AIRO - AIRO GIOVANI)

Belgian Society for Radiation Oncology (BeSTRO)

Israeli Society for Clinical Oncology and Radiotherapy (ISCORT)

Royal Australian and New Zealand College of Radiologists (RANZCR)

Spanish Society of Medical Physics (SEFM)

Spanish Society for Radiotherapy and Oncology (SEOR)

Tunisian Society of Radiation Oncology (STOR)

Young Romanian Radiation Oncologists Group (YRROG)

Joint radiation oncology national societies and other oncology societies

American Association of Physicists in Medicine (AAPM)

Association of Medical Physicists of India (AMPI)

Australasian College of Physical Scientists and Engineers in Medicine (ACPSEM)

Canadian Association of Radiation Oncology (CARO)

European Society of Gynaecological Oncology (ESGO)

International Association for the Study of Lung Cancer (IASLC)

Iranian Society of Clinical Oncology (ISCO)

Japanese Society for Radiation Oncology (JASTRO)

Sociedad Chilena de Radioterapia (SOCHIRA)

Sociedade Brasileira de Radioterapia (SBRT)

South East Asian Radiation Oncology Group (SEAROG)

5. RTT Alliance

European RTT Alliance Members

Austria: Society of Radiological Technology Austria

Belgium: Association Francophone des Infirmiers et Technologues Exerçant en Radiothérapie

Belgium: Vereniging Verpleegkundigen Radiotherapie en Oncologie

Bosnia and Herzegovina: Association of Medical Radiology Engineers in the Federation of Bosnia and Herzegovina

Bulgaria: Bulgarian Society of Radiation Therapy Technicians

Croatia: Croatian Association of Radiation Technologists

Denmark: Radiograf Rådet

Estonia: Estonian Society of Radiographers

France: French Society of Radiologic Technologists

Georgia: Association of Georgia Radiation Treatment Therapists

Ireland: Irish Institute of Radiography and Radiation Therapy

Italy: Italian Association of Radiation Therapist and Medical Physic Technologists

Macedonia: Association and Chamber of Radiological Technologists of Macedonia

Malta: Society of Medical Radiographers

Poland: Polish Society of Electroradiology

Portugal: Portuguese Association of Radiation Therapists

Serbia: Serbian Society of Radiotherapy Technicians

Spain: Spanish Society for Radiotherapy and Oncology

Switzerland: Swiss Association of Radiographers

Turkey: Society of Radiation Therapy Technologists

Global RTT Alliance Members

Brazil: Associação de Técnicos e Tecnólogos em Radioterapia do Rio Grande do Sul

Chile: Sociedad Chilena de Radioterapia Oncológica

India: Association of Radiation Therapy Technologist of India

Tanzania: Radiotherapists' Association of Tanzania

6. Institutional Members

Belgium

AZ Turnhout
CHU Liège
GZA Ziekenhuizen, Sint Augustinus - Iridium
Kankernetwerk Antwerpen
Institut Jules Bordet
University Hospital Gasthuisberg (UZ Leuven)
Universitair Ziekenhuis Brussel

Czech Republic

University Hospital Hradec Kralove

Denmark

Aalborg University Hospital
Odense University Hospital

Estonia

North Estonian Regional Hospital Cancer Center

France

Institut de Radioprotection et de Sûreté
Nucléaire
Centre Oscar Lambret
Centre Léon Bérard
Institut Curie
Institut Gustave Roussy

Germany

Gemeinschaftspraxis fuer Strahlentherapie
Singen-Friedrichshafen
Kliniken Maria Hilf
Klinikum Rechts Der Isar, TU Munich
Klinik und poliklinik für Strahlentherapie und
Radioonkologie (Munich)

Hungary

University of Debrecen Clinic of Oncology

Italy

AOU Careggi - University of Florence
Fondazione IRCCS Istituto Nazionale Tumori
Humanitas Cancer Center
Fondazione CNAO

The Netherlands

Leiden University Medical Center
MAASTRO
NKI - Netherlands Cancer Institute
Radboud University Medical Center
Radiotherapiegroup (Deventer)
The Institute of Cancer Research
UMC Utrecht
VU University Medical Center
Maastricht University

Poland

Greater Poland Cancer Center

Portugal

Joaquim Chaves Clinicas Medicas Ambulatorio

Romania

Regional Institute of Oncology Iasi

Russia

OncoStop

Spain

Institut IMOR
Fundacio Institut d'Investigació Biomèdica de
Bellvitge (IDIBELL)

Sweden

Karolinska University Hospital
Södersjukhuset AB

Switzerland

Basel, St. Claraspital
Basel, Universitäts Spital Basel (USB)
Bellinzona, Ospedale San Giovanni (EOC)
Bern, Inselspital (Universitäts Spital Bern)
Chur, Kantonsspital Graubünden (KSGR)
Fribourg, Hôpital cantonal (HFR)
Genève, Hôpitaux Universitaires (HUG)
Genolier, Clinique de Genolier
La Chaux-de-Fonds, Réseau hospitalier
neuchâtelois (RHNe)
Lausanne, Centre Hospitalier Universitaire
Vaudois (CHUV)
Lausanne, Clinique La Source
Lausanne, Hirslanden Clinique de Bois-Cerf
Lugano, Gruppo Ospedaliero Moncucco
Luzerner Kantonsspital
Paul Scherrer Institut (PSI)
Radio-Onkologie-Zentrum KSA-KSB
Sion, Hopital du Valais
St. Gallen, Kantonsspital (KSSG)
Winterthur, Kantonsspital Winterthur (KSW)
Zürich, Stadtpital Triemli
Zürich, Universitäts Spital Zürich (USZ)

UK

Velindre University NHS Trust
Western General Hospital, Edinburgh Cancer
Centre

Zambia

Cancer Diseases Hospital

7. Radiotherapy and Oncology and open access journals

Radiotherapy and Oncology Editorial Board

Editor-in-Chief

Michael Baumann, MD - Heidelberg, Germany

Editor-in-Chief Emeritus

Jens Overgaard, MD - Aarhus, Denmark

Emeritus Physics Editor

David I. Thwaites, PhD - Leeds, UK

Editors

Marianne Aznar - Manchester, UK

Rob Coppes - Groningen, The Netherlands

Eric Deutsch - Villejuif, France

Dietmar Georg - Vienna, Austria

Karin Haustermans - Leuven, Belgium

Peter Hoskin - Northwood, UK

Albert van der Kogel - Madison, Wisconsin, USA

Mechthild Krause - Dresden, Germany

Eric F. Lartigau - Lille, France

Anne W. M. Lee - Shenzhen, China

Steffen Löck - Dresden, Germany

Birgitte Offersen - Aarhus, Denmark

Vincenzo Valentini - Roma, Italy

Uulke Van der Heide - Amsterdam, The Netherlands

Editorial Board

Markus Alber - Heidelberg, Germany

Ane L. Appelt - Leeds, UK

Pierre Blanchard - Villejuif, France

Michel Bolla - Grenoble, France

Josep M. Borrás - Barcelona, Spain

Thomas Bortfeld - Boston, Massachusetts, USA

Jean Bourhis - Lausanne, Switzerland

Michael Brada - Wirral, UK

Jan Bussink - Nijmegen, The Netherlands

Rebecca Bütof - Dresden, Germany

Felipe A. Calvo - Madrid, Spain

Anthony Chalmers - Glasgow, UK

Juanita M. Crook - Kelowna, British Columbia, Canada

Olav Dahl - Bergen, Norway

Dirk De Ruyscher - Maastricht, The Netherlands

Avraham Eisbruch - Ann Arbor, Michigan, USA

Sara Faithfull - Guildford, UK

Claudio Fiorino - Milano, Italy

Emmanouil Fokas - Frankfurt am Main, Germany

Daniel Richard Gomez - Houston, Texas, USA

Alfonso Gomez-Iturriaga - Bizkaia, Spain

Cai Grau - Aarhus, Denmark

Vincent Grégoire - Lyon, France

Anca-Ligia Grosu - Freiburg, Germany

Matthias Guckenberger - Zurich, Switzerland

Xiashan Hao - Tianjin, China

Semi Harrabi - Heidelberg, Germany

Ben Heijmen - Rotterdam, The Netherlands

Coen W. Hurkmans - Eindhoven, The Netherlands

Geert O. Janssens - Utrecht, The Netherlands

Jing Jin - Beijing, China

Johannes H. A. M. Kaanders - Nijmegen, The Netherlands

Orit Kaidar-Person - Tel Aviv, Israel

Joanna Kazmierska - Poznan, Poland

Lucyna Kepka - Warszawa, Poland

Tommy Knöös - Lund, Sweden

Tommy Kron - Melbourne, Victoria, Australia

Philippe Lambin - Maastricht, The Netherlands

Johannes A. Langendijk - Groningen, The Netherlands

Michelle Leech - Dublin, Ireland

Zhongxing Liao - Houston, Texas, USA

Yvette van der Linden - Leiden, The Netherlands

Philippe Maingon - Paris, France

Gert de Meerleer - Leuven, Belgium

Bernard J. Mijnheer - Amsterdam, The Netherlands

Giuseppe Minniti - Siena, Italy

Gerard C. Morton - Toronto, Ontario, Canada

Ludvig Muren - Aarhus N, Denmark

Ursula Nestle - Freiburg, Germany

Maximilian Niyazi - Munich, Germany

Bradley R. Pieters - Amsterdam, The Netherlands

Philip Poortmans - Wilrijk-Antwerp, Belgium

Richard Pötter - Wien, Austria

Dirk Rades - Lübeck, Germany

Carl Salembier - Brussels, Belgium

Frank André Siebert - Wiener Neustadt, Austria

Kari J. Tanderup - Aarhus, Denmark

Daniela Thorwarth - Tübingen, Germany

Wolfgang Tome - Bronx, New York, USA

Trine Tramm - Aarhus, Denmark

Esther Troost - Dresden, Germany

Conchita Vens - Amsterdam, The Netherlands

Marcel Verheij - Nijmegen, The Netherlands

Dirk Vordermark - Halle, Germany

Marie-Catherine Vozenin - Lausanne, Switzerland

Henning Willers - Boston, USA

Bo Xu - Chongqing, China

Zhen Zhang - Shanghai, China

Daniel Zips - Berlin, Germany

Past Editors

Harry Bartelink

Emmanuel van der Schueren

Clinical and Translational Radiation Oncology

Editors

Pierre Blanchard - Villejuif, France

Daniel Zips - Berlin, Germany

Associate Editors

Pierfrancesco Franco - Vercelli, Italy

Joanna Kazmierska - Poznan, Poland

Guopei Zhu - Shanghai, China

Editorial Board Members

Meritxell Arenas Prat - Reus, Spain

Alejandro Berlin - Toronto, Canada

Jean-Emmanuel Bibault - Paris, France

Pierluigi Bonomo - Firenze, Italy

Gerben Borst - Amsterdam, The Netherlands

Ross Carruthers - Glasgow, UK

Supriya Chopra - Mumbai, India

Monique De Jong - Amsterdam, The Netherlands

Andre Dekker - Maastricht, The Netherlands

Ludwig Dubois - Heerlen, The Netherlands

Dan Duda - Boston, USA

Emmanouil Fokas - Frankfurt am Main, Germany

Steven J. Frank - Houston, USA

Maria Gambacorta - Rome, Italy

Cihan Gani - Tübingen, Germany

Morten Høyer - Aarhus, Denmark

Anna Kirby - London, UK

Pedro C. Lara - Las Palmas de Gran Canaria, Spain

Pernille Lassen - Aarhus, Denmark

Cécile Le Péchoux - Villejuif, France

Laure Marignol - Dublin, Ireland

Brian O'Sullivan - Toronto, Canada

Xiaomin Ou - Shanghai, China

Ian Pereira - Kingston, Canada

Paul Martin Putora - St Gallen, Switzerland

Maximilian Schmid - Wien, Austria

Esther Troost - Dresden, Germany

Physics and imaging in Radiation Oncology

Editor-in-Chief

Ludvig Muren - Aarhus N, Denmark

Daniela Thorwarth - Tübingen, Germany

Editorial Board Members

Jan Bussink - Nijmegen, The Netherlands

Catharine Clark - Guildford, UK

Luca Cozzi - Milano, Italy

Wouter van Elmpt - Maastricht, The Netherlands

Claudio Fiorino - Milano, Italy

Peter Greer - Callaghan, Australia

Coen Hurkmans - Eindhoven, The Netherlands

Tomas Kron - Melbourne, Australia

Pietro Mancosu - Rozzano, Italy

Vitali Moiseenko - San Diego, La Jolla, USA

Jasper Nijkamp - Aarhus, Denmark

Sara Margareta Cecilia Pilskog - Bergen, Norway

Kathrine Redalen - Trondheim, Norway

Christian Richter - Dresden, Germany

Núria Sala - Barcelona, Spain

Jan-Jakob Sonke - Amsterdam, The Netherlands

Jamema Swamidas - Mumbai, India

Neelam Tyagi - New York, USA

Uulke Van der Heide - Amsterdam, The Netherlands

Dirk Verellen - Antwerp, Belgium

Technical Innovations and Patient Support in Radiation Oncology

Editor-in-Chief

Michelle Leech - Dublin, Ireland

Editorial Board Members

Nigel Anderson - Heidelberg, Australia

Nicolaus Andratschke - Zurich, Switzerland

Suzanne van Beek - Amsterdam, The Netherlands

Luca Boldrini - Roma, Italy

Monica Buijs - Amsterdam, The Netherlands

Mikki Campbell - Ottawa, Canada

Mary Coffey - Dublin, Ireland

Geoffrey P Delaney - Sydney, Australia

Colleen Dickie - Toronto, Canada

Aileen Duffton - Glasgow, UK

Sara Faithfull - Guildford, UK

Gerry Hanna - Melbourne, Australia

Suneil Jain - Belfast, UK

Rianne de Jong - Amsterdam, The Netherlands

Pia Krause Møller - Odense, Denmark

Gavin Lawler

Aidan Leong - Dunedin, New Zealand

Mirjam Mast - Leidschendam, The Netherlands

Helen Anne McNair - London, UK

Poonam Negi - Mumbai, India

Sophie Perryck - Zurich, Switzerland

Philipp Scherer - Salzburg, Austria

Hannah Tharmalingam - Northwood, UK

Kenton Thompson - Melbourne, Australia

Yat Man Tsang - Toronto, Ontario, Canada

Michael Velec - Toronto, Ontario, Canada

Sharon Wong - Singapore

8. Awards

ESTRO Award Lectures

Emmanuel Van der Schueren Award

Peter Hoskin (UK)
Radiotherapy: Art or science?

Jens Overgaard Legacy Award

Birgitte Vrou Offeren (DK)
Evidence generating radiation therapy trials and guidelines through collaboration

Donal Hollywood Award

Linda Kerkmeijer (NL)
Patterns of failure in the phase III randomized controlled FLAME trial for localized prostate cancer

Klaas Breur Award

Jan Legendijk (NL)
Real-time MRI guided radiotherapy: The next generation standard?

Honorary Physicist

Corinne Faivre-Finn (UK)
The last of the Honorary Physicists

GEC-ESTRO Iridium 192 Award - In Memoriam of Janusz Skowronek

Piotr Wojcieszek on behalf of Janusz Skowronek (PL)
You'll never walk alone - The lesson Late Prof Janusz Skowronek taught me

Award Presentations

Lifetime Achievement Awards

Volker Budach (DE)
David Dearnaley (UK)
Hakan Nyström (SE)
Lena Specht (DK)

Honorary Member Awards

Liselotte Højgaard (DK)
May Abdel-Wahab (AT)
Thomas Bortfeld (USA)

ESTRO Academic Award

Jack Fowler University of Wisconsin Award
Sharbacha Edward (USA)
Sources of errors in radiotherapy as assessed with the IROC lung, head & neck and spine phantoms

Company Awards

ESTRO Elekta Brachytherapy Award

Ignacio Visus (ES)
HDR brachytherapy boost improves metastatic free survival in high and very-high risk prostate cancer

GEC-ESTRO Best Junior Presentation - sponsored by Elekta Brachytherapy

Teun van Wagenberg (NL)
Brachytherapy treatment verification using a moving phantom

Best Paper Awards

Best Clinical Paper Award

Trine Tramm (DK)
CD8 positive cells indicate gain of postmastectomy radiotherapy: A study of the DBCG82bc cohort

Best Physics Paper Award

Vineet Mohan (NL)
Salivary gland dose response modelling using PSMA PET/CT

Best RTT Paper Award

Petra Klinker (NL)
Predicted reduction in Δ NTCP by model based selected proton therapy for oesophageal cancer patients

Best Interdisciplinary Paper Award

Yolande Lievens (BE)
Coverage with evidence development: Generating real-life evidence on SBRT in Belgium

Best Radiobiology Paper Award

Brita Singers Sørensen (DK)
Differential effect of PBS Proton FLASH on tumor control and skin toxicity in a mouse leg model

Best Brachytherapy Paper Award

Monica Serban (CA)
Effect of dose and fractionation de-escalation in low-risk cervix cancer treated with EBRT and BT

Young Researcher Awards

ctRO Award – sponsored by Elsevier

Sara Reina (IT)
Simulation-CT Skeletal Muscle Index as a Biomarker for CRT compliance and survival in rectal cancer

phiRO Award – sponsored by Elsevier

Guus Grimbergen (NL)
Dosimetric impact of intrafraction upper abdominal tumor motion during MR-guided SBRT

tipsRO Award – sponsored by Elsevier

Sophie Alexander (UK)
Systematic multi-disciplinary sequence evaluation for integration into the MR-linac workflow

9. Newsletter

Corners' Editors

Read it Before Your Patients corner

Philippe Lambin
Hans Kaanders
Evert van Limbergen

Physics corner

Laura Cella
Alan McWilliam
Kathrine Røe Redalen

Brachytherapy Corner

Bradley Pieters
Peter Hoskin
Åsa Carlsson Tedgren

RTT corner

Ilija Čurić
Isabel Lobato
Annette Schouboe
Ludwig Van Den Berghe

Radiobiology corner

Radiobiology Committee

ROSQ

Mary Coffey

Course reports

Education team

Young ESTRO corner

Jenny Bertholet
Bartłomiej Tomasik

ESTRO

European Society
for Radiotherapy & Oncology

Avenue Marnix 17
1000 Brussels
Belgium



WWW.ESTRO.ORG

